Dr. Chien is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 Fourth St
Helen Diller Comprehensive Cancer Center
San Francisco, CA 94158Phone+1 415-353-7070Fax+1 415-353-9898
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2006
Harvard Medical SchoolClass of 2003
Certifications & Licensure
CA State Medical License 2006 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Investigating the Impact of Tamoxifen Therapy on Ovarian Aging Start of enrollment: 2011 Jun 01
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Start of enrollment: 2020 Feb 05
Publications & Presentations
PubMed
- 1 citationsSynchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.Jordyn Silverstein, Francis Wright, Dalila Stanfield, Amy Jo Chien, Jasmine M Wong
The Oncologist. 2024-09-06 - A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, Chiara A Wabl, Michael Assefa
Breast Cancer Research and Treatment. 2024-01-01 - 2 citationsCrofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.Saya Jacob, MacKenzie Johnson, Brianna Roque, Laura Quintal, Hope S Rugo
Clinical Breast Cancer. 2023-10-01
Lectures
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast canc...2019 ASCO Annual Meeting - 6/1/2019
- UCSF Asian Health SymposiumUniversity of California, San Francisco, California - 2/9/2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
